Essent debuts new stem cells for research

By The Science Advisory Board staff writers

June 9, 2021 -- Nonprofit biotechnology firm Essent Biologics has launched human mesenchymal stem cells (hMSCs) for applications in regenerative medicine and biopharmaceutical and cell therapy research.

The stem cells are recovered, expanded, and cryopreserved without the use of antibiotics or animal products. To ensure potency, each vial contains more than 1 million cells at thaw and a passage level of P0 or P1.

Full donor information and a source biopsy are also available with each stem cell order.

Essent Biologics has launched human mesenchymal stem cells for regenerative medicine and biopharmaceutical and cell therapy research.
Essent Biologics has launched human mesenchymal stem cells for regenerative medicine, biopharmaceutical, and cell therapy research. Image courtesy of Essent Biologics.

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter